Psychotic episodes -- like hallucinations or delusions -- related to dementia can be scary for all involved. But there are ways to diagnose and treat the condition.

(StatePoint) Approximately 2.4 million people or 30 percent of people living with dementia in the U.S. may experience hallucinations and delusions associated with dementia-related psychosis. These … ...

In April 2021, the FDA rejected the Nuplazid application for dementia-related psychosis. The regulator told Acadia that the subgroups lacked evidence to show the drug’s efficacy.

They found that across multiple different psychotic disorders, and regardless of the age at which someone first developed their mental illness, there was a higher risk of dementia later in life.

Teams of scientists warn in two recently published medical research papers that marijuana leaves people vulnerable to developing dementia and likely contributes to psychosis. On April 14, the ...

Anti-psychotic drugs should be a last resort. Most antipsychotic medications, including all that were included in the study, aren’t approved by the U.S. Food and Drug Administration to treat ...

The Food and Drug Administration has decided not to approve an expanded use of the psychosis drug pimavanserin (Nuplazid) to treat patients with Alzheimer’s disease. Nuplazid was approved in ...

Dementia-related psychosis is more than just upsetting. It can affect the health and safety of the person with dementia, and those who care for them.